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1. Introduction
  Brucellosis is an anthropo zoonosis which is distributed 
widely in the world. Brucella melitensis (B. melitensis), 
Brucella bovis and Brucella suis are three main epidemic 
brucelloses in China, among which B. melitensis is the 
most common[1]. B. melitensis can interfere with many 
organs through the infection by contact with skin mucous 
membranes, digestive tract and respiratory tract[2]. A 
total of 19 Brucella strains were separated from patients 
hospitalized in our hospital from January 2010 to June 2012, 
including 17 blood samples, 1 bone marrow sample and 1 
cerebrospinal fluid sample, and they were all B. melitensis. 
The bacteriostatic actions of antimicrobial agents in 
common usage were reported in the following.
2. Materials and methods
2.1. Clinical data
  A total of 19 patients admitted between January 2010 
and June 2012 had fever in different degree with the body 
temperature of 37.9-40.9 曟, averaged at 38.9 曟. There were 
12 cases with typical abortus fever, 2 with remittent fever 
and 5 with irregular fever. All the cases had joint pain. 
There were 12 cases with 3 months course, 6 cases with 3-6 
months and 1 case with longer than 6 months, and 2 cases 
were once diagnosed as rheumatic arthritis. Among these 19 
patients, 15 had the contact history of cattle and/or sheep, 
2 took roast mutton, 1 drank goat’s mild and 1 raised pet in 
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the house. Brucella was cultured from al 19 patients.    
2.2. Reagent and instrument
  Gentamicin (GEN), ampicillin(AMP), rifampicin(RIF), 
amikacin (AMK), ceftazidime (CAZ), levofloxacin(LVF), 
sulfamethoxazole-trimethoprim (SXT), doxycycline (DOX); 
E-Test paper was purchased from Sweden AB-Biodisk 
Company.  M-H agar was purchased from Beijing Aoboxing 
Bio-tech Co., LTD.
  Bact/Alert 3D automatic blood culture system and VITEK栻
automatic Bacteria analyzer were purchased from the French 
BioMérieux Company.   
2.3. Methods
2.3.1. Culture and identification of bacteria 
  A total of 16-20 mL blood was extracted from patients and 
injected into the blood culture aerobic bottle and anaerobic 
bottle specialized for Bact/Alert 3D instrument. When the 
instrument indicated positive, the positive bottle was taken 
out for film preparation, Gram’s staining and subcultivation 
in blood agar plate, chocolate plate and MacConkey plate. 
Then the plates were cultured in the 5% CO2 environment. 
The acquired pure bacteria were identified by VITEK栻
automatic Bacteria analyzer.
2.3.2. Susceptibility test
  The minimal inhibitory concentration (MIC) of strain was 
detected by E-Test method. The bacteria solution in 0.5 
McFarland units was evenly spread in the M-H blood agar 
plate. After 5 min, E-Test paper was attached on it. After
10 min at room temperature, the plate was then cultured 
in the environment containing 5% CO2 at 35 曟 for 24 h. 
The rate of bacteriostasis was determined according to the 
CLSI M100-22 standard (MIC explanation for bacteria not 
belonging to Enterobacteriaceae).  
 
3. Results
3.1. Growth characteristics and identification results of 
bacteria
  The mean alarm time of the 19 blood cultures was 52.7 h
with a minimum of 39.3 h and a maximum of 87.9 h. 
After subcultivation in blood plate, chocolate plate and 
MacConkey plate and cultured for 48 h at 35 曟, the round, 
protuberant, ivory-white, moist and anhemolytic bacterial 
colonies with 1-2 mm in size can be found in blood plate 
and chocolate plate, and no colony can be found in the 
MacConkey plate. Gram staining was Gram-negative small 
ball bacili, weak and distributed like silver sand. Brucella 
diagnosis indicated the positive serum. The results were 
positive in the tests of oxidase and catalase and tolerance 
tests of sulfur and fuchsine. The identification result of 
VITEK栻automatic bacteria analyzer was B. melitensis.  
3.2. MIC
  The MIC range of CAZ was 2.0-8.0 mg/L, RIF was 0.06-
2.0 mg/L, AMK was 4.0-12.0 mg/L, LVF was 2.0-8.0 mg/L, 
DOX was 8.0-32.0 mg/L, SXT was 4.0-16.0 mg/L, AMP was
1.5-2.0 mg/L and GEN was 0.50-0.75 mg/L (Table 1, 2).  
Table 1 
MICs of 19 B. melitensis strains against 8 antimicrobial agents (mg/L).
No GEN AMP RIF AMK CAZ LVF SXT DOX
1 0.50 2.0 0.06 12.0 2.0 2.0 16.0 32.0
2 0.75 2.0 0.06 12.0 8.0 8.0   4.0 16.0
3 0.75 1.5 0.06   4.0 4.0 2.0   8.0 16.0
4 0.50 2.0 2.00   8.0 2.0 2.0   8.0   8.0
5 0.75 1.5 0.75   8.0 4.0 8.0   8.0   8.0
6 0.50 2.0 0.75   8.0 2.0 2.0   4.0 32.0
7 0.50 2.0 0.06   4.0 8.0 2.0   4.0 16.0
8 0.50 1.5 2.00   8.0 2.0 2.0   8.0 16.0
9 0.50 1.5 0.75   4.0 8.0 4.0 16.0   8.0
10 0.75 2.0 0.75   8.0 2.0 4.0   4.0 32.0
11 0.75 1.5 0.06 12.0 4.0 4.0   4.0 16.0
12 0.75 1.5 0.06   4.0 4.0 8.0   8.0 16.0
13 0.75 1.5 2.00   4.0 2.0 2.0 16.0   8.0
14 0.75 1.5 0.06   4.0 4.0 8.0   4.0 32.0
15 0.75 2.0 2.00   4.0 2.0 4.0   4.0 16.0
16 0.50 2.0 0.06   4.0 8.0 2.0   8.0   8.0
17 0.50 2.0 2.00   8.0 4.0 8.0 16.0   8.0
18 0.75 2.0 0.06   4.0 2.0 8.0   4.0   8.0
19 0.75 2.0 2.00   8.0 4.0 2.0   8.0   8.0
Table 2 
Results of MIC range, MIC50 and MIC90 (mg/L).
Antimicrobial agent MIC range MIC50 MIC90 Bacteriostatic rate 
(% )
GEN 0.50-0.75 0.75   0.75 100.00
AMP 1.50-2.00 2.00   2.00 100.00
RIF 0.06-2.00 0.75   2.00 --
AMK   4.00-12.00 8.00 12.00 100.00
CAZ 2.00-8.00 4.00   8.00 100.00
LVF 2.00-8.00 4.00   8.00 68.42
SXT   4.00-16.00 8.00 16.00 0.00
DOS   8.00-32.00 16.00 32.00 42.11
 
4. Discussion
  Brucella is a Gram-negative Bacillus pumilis which can 
cause infectious abortion of female animal, and cattle, sheep 
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and swine are most susceptible to Brucella. Brucella is a 
zoonotic pathogen[3]. The infected animals continuously 
excrete Brucella through secretion and excretion substance 
(milk, sperm, vaginal secretion, dung and urine), especially 
the numerous pathogenic bacteria excreted with aborted 
fetus, afterbirth and amniotic fluid. Brucella becomes the 
most dangerous communicable disease[4]. Since Brucella 
was firstly formally reported by Boone in Chongqing in 1905, 
Brucellosis has been found in 170 of the more than 200 
countries and regions in all continents[5-9]. The epidemic 
situation of Brucellosis in human and animals shows the 
ascending tendency in domestic and abroad[10,11]. The 
development of Brucellosis is very complex. Brucellosis is 
very complex and hard to be cured for the following reasons. 
Firstly, Brucellosis is associated with bacteremia, toxemia 
and allergy. Secondly, Brucella invades many organs. 
Thirdly, antibacterials and antibody can hardly enter the 
cell[12-14].
  According to the course of disease, Brucellosis can be 
divided into acute stage (within 6 months) and chronic 
phase (more than 6 months)[15]. Acute brucellosis would 
cause the systemic proliferation of reticuloendothelial 
cells accompanied by sepsis and the damage on nervous, 
circulating and genital system, especially on bone joint 
system. The current treatment of Brucellosis in acute 
stage generally adopts the internationally recommended 
oral administration of Tetracycline and intramuscular 
injection of streptomycin[16]. However, the chronic phase is 
characterized by proliferation of tissue cells and formation 
of granuloma. Fibrosclerosis of granulation tissue in some 
patients is the basis of having sequela[17].           
  In this experiment, LVF, GEN, RIF and CAZ belong to 
bactericidal agents. LVF is a kind of quinolone drugs whose 
mechanism is inhibiting the gyrase of DNA to make the DNA 
unable to form superhelix which can result in irreversible 
damage on chromatosome, inhibiting the cell division of 
bacteria and producing rapid bactericidal effect. Belonging 
to rifomycins, RIF can block the synthesis of bacteria RNA 
and protein, having obvious killing effect on the bacteria 
inside and outside the cell[18]. CAZ has a high effect on 
bacteria in idophase and mainly acts on the bacterial cell 
wall, but it has no influence on the already synthesized cell 
wall in the quiescent condition[19]. From the results of this 
study, the MIC of RIF was in low level with good bactericidal 
activity, which is consistent with the report[16]. RIF has 
long been regarded as the first choice in treating Brucella 
infection, and its clinical therapy is generally satisfactory. 
But some patients cannot use RIF for a long time because 
of the obvious gastrointestinal reaction. In this case, other 
alternative medicines or combined use of other drugs should 
be adopted to reduce patients’ discomfortableness. The 
MIC values of LVF and CAZ were in medium level, but the 
bacteriostatic rate of CAZ was better. There is a report on 
the successful treatment of brucellosis by LVF and CAZ[20], 
and therefore, they can be the second choice. AMK and 
GEN belong to aminoglycoside antibiotics. They have high 
bactericidal activity to Br.melitensis like AMP, but there are 
only a few case reports on treatment of Brucella infection 
by GEN or AMP[21,22]. The MICs of DOX to 19 strains were 
all above 8mg/L with the highest of 32 mg/L, which was 
consistent with what reported several years ago[23]. The 
bacteriostatic rate of SXT was low, and it can not be selected 
as the therapeutic medicine from the antibacterial activity.     
  Among the 19 Br.melitensis patients observed in this 
study, 15 hospitalized patients received the therapy of 
oral administration of RIF and intramuscular injection of 
streptomycin (course of treatment: 4 weeks) after diagnosed 
as Brucella infection. After medication for 2 weeks, the 
patients got better in different degrees. The other 4 cases 
are out-patients who cannot be traced and followed-up, 
and the treatment and prognosis remain unknown. The 
authors believe that Brucella infection would invade many 
systems of body; each patient would show different clinical 
symptoms and physical signs according to different physical 
quality and immune competence; the tolerance of drug is 
also different from each other. Therefore, the therapeutic 
regimen of RIF combined with streptomycin or DOX is far 
from enough. Through this experiment, it can be clearly seen 
that AMP and aminoglycosides drugs are also good choices. 
For the early rehabilitation of patients in clinic, drugs should 
be flexibly chosen according to the individual difference 
and results of susceptibility test. 
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